

TABLE OF CONTENTS

October 20, 2008

No. 2111

BUSINESS

- 1 Mediceo Paltac, Alfresa to Merge to Create a ¥4 Trillion Wholesaler
 - Takeda, Nihon Chouzai Welcome the Move
 - Suzuken Shows Interest in Following Suit
 - Main Objective Is Cost-cutting
 - New Company Should Better Fulfill Wholesalers' Functions
 - Proposed Merger May Present Problems with Antimonopoly Act
- 3 Astellas Completes New Buildings in Its Tsukuba Research Center
- 4 Daiichi Sankyo Aims at Top Share in CV Field: Mr Shoda
 - Companies with New Drugs to Survive under New Drug Pricing System
- 4 Shionogi Completes TOB on Sciele
- 5 AnGes MG Negotiates Rights to New-Type Influenza DNA Vaccine with Vical
- 5 Eli Lilly to Acquire ImClone for US\$6.5 Billion
- 6 Novartis Enhances Sales/Marketing by Therapeutic Category
- 6 **BUSINESS NEWS IN BRIEF**
 - Alfresa Pharma to Construct New Plant
 - Mediscience Planning Goes Public

REGULATORY

- 8 Thalidomide to Be Approved for Multiple Myeloma
 - Price Must Enable Proper Safety Management without Interfering with Free Access
 - Fujimoto Should Cut Costs without Jeopardizing Safety Measure
 - Prifenidone Recommended for Approval
- 9 Industry Should Stress Contribution to Healthcare: Mr Kinoshita
 - Drug Substances Account for 84% of Applications for Overseas GMP Inspections
- 9 Kissei's Silodosin Approved in US
- 10 To Promote Use of Generics or Cut Prices of Original Drugs?
 - Will Savings from Use of Generics Be Used to Promote Innovation?
 - Generic Manufacturers Have Only 10 or So MRs in US: Dr Kato
 - Original Makers Are Not Responsible for Failure to Promote Use of Generics: Mr Koga
 - FPMAJ's New Proposal Is Realistic: Mr Koga
 - Allow Companies to Decide Prices of Their Own Drugs: Dr Fujii

NEW PRODUCTS

- 12 **NEW PRODUCTS**
 - Pfizer Japan: Mycobutin Capsule for Mycobacteriosis
 - Astellas Pharma: Irribow for Diarrhea-Predominant IBS

R&D

- 12 Otsuka Extends Joint Research Program with Galenea for 1 Year
- 13 **R&D NEWS IN BRIEF**
 - Genentech, GlycArt, Roche Tie Up for Potential Cancer Therapy
 - Takara Bio to Test HSV-TK Gene Therapy for Leukemia
 - NVA237 Shows Promising Efficacy, Tolerability: Sosei, Novartis
 - Liraglutide alone More Effective than Glimpiride: Novo Nordisk
 - Prof. Yamanaka Established iPS Cells without Using Virus Vector

MEDICAL DEVICES

- 14 Teijin Acquires another Home Therapy Equipment Provider in US
- 14 FALCO Signs CYP2D6*4 Gene Patent Licensing Agreement with LGC
- 14 **MEDICAL DEVICE NEWS IN BRIEF**
 - Roche Diagnostics: Amplicor HPV
 - Kyowa Medex Launches Coagtron-180
 - Sekisui Medical Launched Diagnostic Reagent for Diabetes
 - Boston Scientific Celebrates 10th Anniversary of Its Training Center in Miyazaki
 - Koroshio Orders Revision of Package Insert for Ureteral Stents

SELF-MEDICATION

- 16 Industry Split over Online Sale of OTC Drugs
 - There Is No Ground for Banning Online Sale of Class 2 OTC Drugs: Council
 - No Health Problems Reported due to Online Sale of Drugs: Kenko.com.

GENERICS

- 17 % of Prescriptions Permitting Generic Substitution Decreasing: Survey
- 17 67% of Pharmacies Have Demanded Premium for Generics Dispensing System

MEDICAL FACILITIES & NURSING CARE

- 18 Final Draft of Peptic Ulcer Guidelines Approved
 - Conservative Attitude toward Re-eradication by Quinolones
- 18 Routine Use of PCV7 Is Cost-Effective: Wyeth
- 19 Japan's First ACS Patient Registry Study PACIFIC Underway
- 19 **TOPICS**
 - Novo Nordisk to Launch Next Generation of FlexPen